Omeros | OMER - Cash And Equivalent


Omeros reported $1.9M in Cash and Equivalent for its fiscal quarter ending in June of 2025.





Cash And Equivalent Change Date
Adma Biologics USD 87.63M 26.24M Dec/2025
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Cytokinetics USD 129.84M 7.32M Mar/2026
Gilead Sciences USD 7.56B 234M Dec/2025
Heron Therapeutics USD 43.07M 26.55M Sep/2025
Immunic USD 15.48M 19.65M Dec/2025
Insmed USD 510.44M 175.68M Dec/2025
Knight Therapeutics CAD 76.45M 5.43M Dec/2025
MacroGenics USD 57.22M 22.91M Dec/2025
Omeros USD 1.9M 2.36M Jun/2025
Pacira USD 144.31M 14.24M Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Rockwell Medical USD 12.48M 1.09M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sarepta Therapeutics USD 801.28M 188.2M Dec/2025
United Therapeutics USD 1.56B 217M Dec/2025
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026
Xoma USD 143.9M 7.68M Jun/2024